US FDA Approves First-in-Class Drug Trutakna for Adults with IgA Nephropathy

The United States Food and Drug Administration (US FDA) has approved Trutakna (atacicept-vymj), a first-in-class treatment developed by Vera Therapeutics, to reduce proteinuria in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression.

The approval marks an important milestone in the treatment of IgA nephropathy, a serious kidney disease that can gradually lead to kidney failure if left unchecked.

IgA nephropathy occurs when an abnormal form of the immunoglobulin A (IgA) antibody accumulates in the kidneys, triggering inflammation and progressive damage. As the disease advances, protein leaks from the bloodstream into the urine, a condition known as proteinuria, while kidney function steadily declines.

Trutakna is the first FDA-approved medicine designed to target both B cell activating factor (BAFF) and A Proliferation Inducing Ligand (APRIL), two proteins involved in the survival and maturation of certain immune cells. By blocking these pathways, the drug reduces the production of the abnormal IgA antibodies responsible for damaging the kidneys.

The FDA’s decision was supported by results from a randomized, double-blind, placebo-controlled clinical trial involving adults with biopsy-confirmed IgA nephropathy.

During the study, participants received either Trutakna 150 mg, administered by subcutaneous injection once a week, or a placebo. After nine months of treatment, patients receiving Trutakna experienced an average 46 percent reduction in proteinuria compared with those in the placebo group, indicating a significant improvement in one of the disease’s key markers.

The approval was granted under the FDA’s Accelerated Approval pathway, which allows promising treatments for serious conditions to reach patients sooner based on surrogate endpoints that are reasonably likely to predict clinical benefit.

However, the FDA emphasized that it has not yet been established whether Trutakna slows the long-term decline in kidney function in patients with IgA nephropathy.

As part of the accelerated approval requirements, Vera Therapeutics must complete an ongoing confirmatory clinical trial to determine whether the treatment provides sustained protection against worsening kidney disease. Continued FDA approval will depend on verification of this long-term clinical benefit.

The FDA also issued important safety warnings. Because Trutakna suppresses the immune system, it may increase the risk of infections. Healthcare providers are advised to screen patients for active infections before initiating treatment and to monitor them closely throughout therapy.

In addition, the agency cautioned that the drug may reduce the body’s immune response to vaccines and increase the risk of infection from live vaccines. As a result, the administration of live vaccines is not recommended within 30 days before starting treatment or while receiving Trutakna.

Recognizing its potential to address a significant unmet medical need, the FDA granted Trutakna both Priority Review and Breakthrough Therapy designation ahead of its approval.

The approval offers a new treatment option for adults living with IgA nephropathy and represents a significant advancement in the management of a disease that has long had limited targeted therapies. While further research is needed to confirm its long-term impact on preserving kidney function, Trutakna provides new hope for patients at risk of progressive kidney damage.

Source: Joynewsonline